• 1
    Collison CH, Sinal SH, Jorizzo JL, Walker FO, Monu JU, Snyder J. Juvenile dermatomyositis and polymyositis: a follow-up study of long-term sequelae. South Med J 1998; 91: 1722.
  • 2
    Chalmers A, Sayson R, Walters K. Juvenile dermatomyositis: medical, social and economic status in adulthood. Can Med Assoc J 1982; 126: 313.
  • 3
    Huber AM, Lang B, LeBlanc CM, Birdi N, Bolaria RK, Malleson P, et al. Medium-and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. Arthritis Rheum 2000; 43: 5419.
  • 4
    Ruperto N, Ravelli A, Pistorio A, Ferriani V, Calvo I, Ganser G, et al, for the Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG). The provisional Paediatric Rheumatology International Trials Organisation/American College of Rheumatology/European League Against Rheumatism disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: a prospective validation study. Arthritis Rheum 2008; 59: 413.
  • 5
    Miller FW, Rider LG, Chung YL, Cooper R, Danko K, Farewell V, et al. Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology (Oxford) 2001; 40: 126273.
  • 6
    Ravelli A, Trail L, Ferrari C, Ruperto N, Pistorio A, Pilkington C, et al. Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients. Arthritis Care Res (Hoboken) 2010; 62: 6372.
  • 7
    Fraser DD, Frank JA, Dalakas M, Miller FW, Hicks JE, Plotz P. Magnetic resonance imaging in the idiopathic inflammatory myopathies. J Rheumatol 1991; 18: 1693700.
  • 8
    Hernandez RJ, Sullivan DB, Chenevert TL, Keim DR. MR imaging in children with dermatomyositis: musculoskeletal findings and correlation with clinical and laboratory findings. AJR Am J Roentgenol 1993; 161: 35966.
  • 9
    Adams EM, Chow CK, Premkumar A, Plotz PH. The idiopathic inflammatory myopathies: spectrum of MR imaging findings. Radiographics 1995; 15: 56374.
  • 10
    Kimball AB, Summers RM, Turner M, Dugan EM, Hicks J, Miller FW, et al. Magnetic resonance imaging detection of occult skin and subcutaneous abnormalities in juvenile dermatomyositis: implications for diagnosis and therapy. Arthritis Rheum 2000; 43: 186673.
  • 11
    McCann LJ, Juggins AD, Maillard SM, Wedderburn LR, Davidson JE, Murray KJ, et al. The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland): clinical characteristics of children recruited within the first 5 yr. Rheumatology (Oxford) 2006; 45: 125560.
  • 12
    Walker UA. Imaging tools for the clinical assessment of idiopathic inflammatory myositis. Curr Opin Rheumatol 2008; 20: 65661.
  • 13
    Gardner-Medwin JM, Irwin G, Johnson K. MRI in juvenile idiopathic arthritis and juvenile dermatomyositis. Ann N Y Acad Sci 2009; 1154: 5283.
  • 14
    Summers RM, Brune AM, Choyke PL, Chow CK, Patronas NJ, Miller FW, et al. Juvenile idiopathic inflammatory myopathy: exercise-induced changes in muscle at short inversion time inversion-recovery MR imaging. Radiology 1998; 209: 1916.
  • 15
    Hilario MO, Yamashita H, Lutti D, Len C, Terreri MT, Lederman H. Juvenile idiopathic inflammatory myopathies: the value of magnetic resonance imaging in the detection of muscle involvement. Sao Paulo Med J 2000; 118: 3540.
  • 16
    Rider LG, Lachenbruch PA, Monroe JB, Ravelli A, Cabalar I, Feldman BM, et al, for the IMACS Group. Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the Myositis Damage Index. Arthritis Rheum 2009; 60: 342535.
  • 17
    Wedderburn LR, McHugh NJ, Chinoy H, Cooper RG, Salway F, Ollier WE, et al. HLA class II haplotype and autoantibody associations in children with juvenile dermatomyositis and juvenile dermatomyositis-scleroderma overlap. Rheumatology (Oxford) 2007; 46: 178691.
  • 18
    Rider LG, Miller FW, Targoff IN, Sherry DD, Samayoa E, Lindahl M, et al. A broadened spectrum of juvenile myositis: myositis-specific autoantibodies in children. Arthritis Rheum 1994; 37: 15348.
  • 19
    Ronnelid J, Helmers SB, Storfors H, Grip K, Ronnblom L, Franck-Larsson K, et al. Use of a commercial line blot assay as a screening test for autoantibodies in inflammatory myopathies. Autoimmun Rev 2009; 9: 5861.
  • 20
    Espada G, Maldonado Cocco JA, Fertig N, Oddis CV. Clinical and serologic characterization of an Argentine pediatric myositis cohort: identification of a novel autoantibody (anti-MJ) to a 142-kDa protein. J Rheumatol 2009; 36: 254751.
  • 21
    Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975; 292: 3447.
  • 22
    Sanner H, Gran JT, Sjaastad I, Flato B. Cumulative organ damage and prognostic factors in juvenile dermatomyositis: a cross-sectional study median 16.8 years after symptom onset. Rheumatology (Oxford) 2009; 48: 15417.
  • 23
    Loge JH, Kaasa S, Hjermstad MJ, Kvien TK. Translation and performance of the Norwegian SF-36 health survey in patients with rheumatoid arthritis. I. Data quality, scaling assumptions, reliability, and construct validity. J Clin Epidemiol 1998; 51: 106976.
  • 24
    Ware JE Jr, Kosinski MA. Physical and mental summary scales: a manual for users of version 1. Lincoln (RI): Quality Metric; 2001.
  • 25
    Bode RK, Klein-Gitelman MS, Miller ML, Lechman TS, Pachman LM. Disease activity score for children with juvenile dermatomyositis: reliability and validity evidence. Arthritis Rheum 2003; 49: 715.
  • 26
    Isenberg DA, Allen E, Farewell V, Ehrenstein MR, Hanna MG, Lundberg IE, et al. International consensus outcome measures for patients with idiopathic inflammatory myopathies: development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology (Oxford) 2004; 43: 4954.
  • 27
    Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 13745.
  • 28
    Singh G, Athreya BH, Fries JF, Goldsmith DP. Measurement of health status in children with juvenile rheumatoid arthritis. Arthritis Rheum 1994; 37: 17619.
  • 29
    Feldman BM, Ayling-Campos A, Luy L, Stevens D, Silverman ED, Laxer RM. Measuring disability in juvenile dermatomyositis: validity of the Childhood Health Assessment Questionnaire. J Rheumatol 1995; 22: 32631.
  • 30
    Hicks J, Wesley R, Koziol D, Smith M, Jain M, Cintas H, et al. Preliminary validation of abbreviated manual muscle testing (MMT) in the assessment of juvenile dermatomyositis (JDM) [abstract]. Arthritis Rheum 2000; 43 Suppl: S195.
  • 31
    Lovell DJ, Lindsley CB, Rennebohm RM, Ballinger SH, Bowyer SL, Giannini EH, et al, and the Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. II. The Childhood Myositis Assessment Scale (CMAS): a quantitative tool for the evaluation of muscle function. Arthritis Rheum 1999; 42: 22139.
  • 32
    Huber AM, Feldman BM, Rennebohm RM, Hicks JE, Lindsley CB, Perez MD, et al, for the Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Validation and clinical significance of the Childhood Myositis Assessment Scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies. Arthritis Rheum 2004; 50: 1595603.
  • 33
    Goutallier D, Postel JM, Gleyze P, Leguilloux P, Van Driessche S. Influence of cuff muscle fatty degeneration on anatomic and functional outcomes after simple suture of full-thickness tears. J Shoulder Elbow Surg 2003; 12: 5504.
  • 34
    Williams MD, Ladermann A, Melis B, Barthelemy R, Walch G. Fatty infiltration of the supraspinatus: a reliability study. J Shoulder Elbow Surg 2009; 18: 5817.
  • 35
    Manlhiot C, Liang L, Tran D, Bitnun A, Tyrrell PN, Feldman BM. Assessment of an infectious disease history preceding juvenile dermatomyositis symptom onset. Rheumatology (Oxford) 2008; 47: 5269.
  • 36
    Pachman LM, Abbott K, Sinacore JM, Amoruso L, Dyer A, Lipton R, et al. Duration of illness is an important variable for untreated children with juvenile dermatomyositis. J Pediatr 2006; 148: 24753.
  • 37
    Constantin T, Ponyi A, Orban I, Molnar K, Derfalvi B, Dicso F, et al. National registry of patients with juvenile idiopathic inflammatory myopathies in Hungary: clinical characteristics and disease course of 44 patients with juvenile dermatomyositis. Autoimmunity 2006; 39: 22332.
  • 38
    Rennebohm RM, Jones K, Huber AM, Ballinger SH, Bowyer SL, Feldman BM, et al, for the Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Normal scores for nine maneuvers of the Childhood Myositis Assessment Scale. Arthritis Rheum 2004; 51: 36570.
  • 39
    Nader GA, Lundberg IE. Exercise as an anti-inflammatory intervention to combat inflammatory diseases of muscle. Curr Opin Rheumatol 2009; 21: 599603.
  • 40
    Park JH, Vansant JP, Kumar NG, Gibbs SJ, Curvin MS, Price RR, et al. Dermatomyositis: correlative MR imaging and P-31 MR spectroscopy for quantitative characterization of inflammatory disease. Radiology 1990; 177: 4739.
  • 41
    Murphy WA, Totty WG, Carroll JE. MRI of normal and pathologic skeletal muscle. AJR Am J Roentgenol 1986; 146: 56574.
  • 42
    Miller FW, Waite KA, Biswas T, Plotz PH. The role of an autoantigen, histidyl-tRNA synthetase, in the induction and maintenance of autoimmunity. Proc Natl Acad Sci U S A 1990; 87: 99337.
  • 43
    Stone KB, Oddis CV, Fertig N, Katsumata Y, Lucas M, Vogt M, et al. Anti–Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy. Arthritis Rheum 2007; 56: 312531.
  • 44
    Mamyrova G, O'Hanlon TP, Monroe JB, Carrick DM, Malley JD, Adams S, et al, for the Childhood Myositis Heterogeneity Collaborative Study Group. Immunogenetic risk and protective factors for juvenile dermatomyositis in Caucasians. Arthritis Rheum 2006; 54: 397987.
  • 45
    Stringer E, Singh-Grewal D, Feldman BM. Predicting the course of juvenile dermatomyositis: significance of early clinical and laboratory features. Arthritis Rheum 2008; 58: 358592.